Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label non-randomized study of SAR444245 with or without other anticancer therapy in relapsed or refractory B-cell lymphoma
MOH_2022-07-07_011890Phase 2Completed
- Sponsor
- Sanofi
- Start
- Mar 2022
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pegenzileukin in classical Hodgkin lymphoma (cHL) and diffuse large B-cell lymphoma (DLBCL) (2 cohorts), sponsored by Sanofi. Primary endpoint: Objective response rate. Started Mar 2022; status: completed.
02
Drugs
pegenzileukin
03
Conditions
classical Hodgkin lymphoma (cHL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on MOH_2022-07-07_011890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-07-07_011890.